 Alnylam Pharmaceuticals Inc NASDAQ: ALNY announced topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in primary hyperoxaluria type 1 PH1 associated with progressive decline in renal function. Lumasiran is an RNAi therapeutic targeting hydroxyacid oxidase 1 HAO1, the gene encoding glycolate oxidase GO. 